- Home
- ITRM vs GNTA Comparison
ITRM vs GNTA Comparison
Compare ITRM & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRM | GNTA |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Ireland | Italy |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 19.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ITRM | GNTA |
|---|---|---|
| Price | $0.03 | $0.70 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 30.9M | 37.5K |
| Earning Date | 05-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $947.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.03 | $0.59 |
| 52 Week High | $1.16 | $10.00 |
Technical Indicators
Market Signals| Indicator | ITRM | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 26.10 | 45.89 |
| Support Level | N/A | $0.61 |
| Resistance Level | $0.39 | $0.76 |
| Average True Range (ATR) | 0.02 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 3.34 | 36.18 |
Price Performance
Historical ComparisonAbout ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.